ArticleEpilepsy & behavior reports2026
Comparative trends in idiopathic epilepsy burden in China and worldwide based on Global Burden of Disease Study 2021.
Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Idiopathic epilepsy, defined by the absence of identifiable structural or metabolic etiologies, remains a significant contributor to the global neurological disease burden. However, long-term comparisons between China and the global level are limited. This study analyzed and compared trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of idiopathic epilepsy between China and the global level from 1990 to 2021, and included predictive analysis of future trends. Methods: The key metrics including incidence, prevalence, mortality, and DALYs, along with their corresponding age-standardized rates, were extracted and analyzed. Joinpoint regression was employed to assess temporal trends, Bayesian age-period-cohort models were used for future projections, and decomposition analysis quantified the contributions of population growth, population aging, and epidemiological changes. Results: From 1990 to 2021, both China and the world showed increasing trends in incidence and prevalence. In contrast, DALYs and mortality decreased significantly, with China showing a more pronounced decline (AAPC: -1.790%; -2.649%) than the global level (AAPC: -0.525%; -0.535%). Decomposition analysis revealed that epidemiologic changes played a greater role in China's DALY and mortality reductions. Projection analysis suggested continued increases in incidence and prevalence, but ongoing declines in DALYs and mortality by 2045, especially in China. Discussion: The burden of idiopathic epilepsy has evolved differently in China compared with global trends, with China experiencing a more substantial reduction in disease severity and mortality. These findings highlight the need for targeted prevention strategies and health system enhancements tailored to specific demographic and epidemiological profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.